Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India

BACKGROUND: Regorafenib is a multikinase inhibitor (MKI) approved for use in multiply pre-treated metastatic colorectal cancers (mCRC). To the best of our knowledge, this is the first report of regorafenib from India. MATERIALS AND METHODS: Records of 23 cases treated with regorafenib at our centre...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Transl Med
Main Authors: Zanwar, Saurabh, Ostwal, Vikas, Gupta, Sudeep, Sirohi, Bhawna, Toshniwal, Anup, Shetty, Nitin, Banavali, Shripad
Formato: Artigo
Idioma:Inglês
Publicado: AME Publishing Company 2016
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4779767/
https://ncbi.nlm.nih.gov/pubmed/27004221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2305-5839.2016.02.05
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares